desk
Share
News Topical, Digital Desk : Pharma sector company Glenmark Pharmaceuticals has released the results for the first quarter (April-June) of the financial year 2026. The company's profits saw a huge decline, the main reason for which is the settlement of a lawsuit in the US. Before the results were released, on Thursday, the stock closed at Rs 2045 per share with a gain of 1.25 per cent.
How were the Q1 results of Glenmark Pharma?
- Profit: There has been a massive decline of 86.2% on yearly basis, the company's profit in the June quarter was Rs 46.8 crore, which was Rs 340.2 crore last year.
- Income: The company's income increased marginally by 0.6% to Rs 3,264 crore as against Rs 3,244 crore last year.
- EBITDA: The company's operating profit i.e. EBITDA declined by 1.4% to Rs 580 crore, which was Rs 588.2 crore last year.
- Margin: Fell from 18.1% to 17.7%.
Impact of US lawsuit on results
The company's results were greatly affected by the settlement of an ongoing antitrust and consumer protection lawsuit in the US. Glenmark has settled with the direct buyer class for $37.75 million (about Rs 323.23 crore), which was included as a provision in this quarter. The company clarified that this settlement is not an admission of any fault or liability.
What did the management say on the results?
Glenmark Pharma Chairman and Managing Director, Glenn Saldanha said, "Although our revenue has grown, Q1 results have been affected by the US settlement. We will focus on our core pharmaceutical business and continue to invest in innovation and strategic partnerships for future growth."
--Advertisement--
